Ownership and insider activity for Aspire Biopharma Holdings, Inc. (ASBP): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management.
Price
| Price | $8.58 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2025-06-05 | Fell Donald G. | P-Purchase | 10,500 | $4K |
| 2025-06-04 | Fell Donald G. | P-Purchase | 9,500 | $4K |
| 2025-06-05 | Fell Donald G. | P-Purchase | 10,500 | $4K |
| 2025-06-04 | Fell Donald G. | P-Purchase | 9,500 | $4K |
| 2023-08-18 | AJJARAPU SURENDRA K | |||
| 2023-08-18 | AJJARAPU SURENDRA K | 6,834,333 | $78.6M | |
| 2023-08-18 | Doshi Mayur Mansukhlal | |||
| 2023-08-18 | Wadhwani Avinash R | |||
| 2023-08-18 | PETERSON MICHAEL L | |||
| 2023-08-18 | Fell Donald G. |
Balance Sheet (10y)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 0 | $497259 | 0 | $3633 | $1.0M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | $36503 | 0 |
| Inventory | 0 | 0 | 0 | 0 | $253160 |
| Total Current Assets | $293221 | $1.1M | $81223 | $147989 | $1.3M |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $293221 | $300.2M | $20.0M | $147989 | $1.3M |
| Accounts Payable | $273 | $180634 | 0 | $310219 | $1.0M |
| Short-term Debt | $238596 | $27967 | $12384 | $1.3M | $1.4M |
| Total Current Liabilities | $293696 | $303323 | $403328 | $1.7M | $7.6M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $293696 | $11.1M | $403328 | $1.7M | $7.7M |
| Retained Earnings | -$25475 | -$9.9M | -$11.3M | -$2.8M | -$27.3M |
| Total Equity | -$475 | $289.1M | $19.6M | -$1.5M | -$6.4M |
| Total Debt | $238596 | $27967 | $12384 | $1.3M | $1.4M |
| Net Debt | $238596 | -$469292 | $12384 | $1.3M | $380874 |
| Working Capital | -$475 | $794429 | -$322105 | -$1.5M | -$6.3M |
Financial Health
| Debt / Equity | -0.22 |
| Current Ratio | 0.17 |
Profitability
| Return on Equity | 383.93% |
| Return on Invested Capital | 395.26% |
| Return on Assets | -1865.68% |
| Gross Margin | -1.87% |
| Operating Margin | -312016.95% |
| Net Margin | -394725.06% |
Related companies: ANNA · BOCN · CAUD · CHAA · CSLM · FIAC · GAMC
Explore sector: Healthcare · Biotechnology
More sections of ASBP: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks